Health Care · Services-Commercial Physical & Biological Research

INCY Incyte SEC Filings & Insider Trading Activity 2026

company
CIK 879169144 filings
S&P 500

INCY at a glance

Incyte (INCY, SEC CIK 879169) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Incyte (INCY) reported revenue of $5.1 billion (up 21.2% from FY2024) and net income of $1.3 billion. Diluted EPS was $6.41.
  • As of September 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Incyte (INCY) shares worth $9.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by CAGNONI PABLO J on November 16, 2026 of 1,765 shares at $120.46 per share.
  • In the last 90 days, INCY insiders reported 0 open-market purchases ($0) and 17 open-market sales ($33.3M) on Form 4, a net sale of $33.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$5.1B
+21.2% vs prior year
Insiders · 90 days
0 buys · 17 sells
Net −$33.3M
13F holders
39 funds
$9.6B · −3 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Biopharmaceutical company focused on development, commercialization, and licensing of innovative drugs
  • New products emphasized: NIKTIMVO commercial launch in Q1 2025; ZYNYZ approved for squamous cell anal carcinoma in Q2 2025
  • Strategic shift: Settlement with Novartis reduces JAKAFI royalty rate by 50% starting Jan 1, 2025, lowering future royalty expenses
  • Quantitative metric: Net income $1,286.7M in 2025 vs $32.6M in 2024; total revenues $5.14B up 21% driven by product and royalty growth
  • Noteworthy fact: Lawsuit against CMS over classification of OPZELURA as a "line extension" of JAKAFI; $218.5M accrued potential rebate liability impacting OPZELURA revenue deductions

Risk Factors

  • Regulatory risk: ongoing contract dispute settlement expense of $242M recognized in fiscal 2025
  • Macroeconomic exposure: 93% of total revenues ($4.8B of $5.1B) from U.S. market concentration
  • Operational risk: elevated external R&D spend of $968M in 2025, reliance on third-party contract manufacturing and research vendors
  • Competitive risk: heightened R&D investment ($1.98B total) to address oncology and dermatology market challenges
  • Financial risk: impairment charge of $76M in 2025 reflecting asset write-downs impacting balance sheet strength

Management Discussion & Analysis

  • Revenue $3.5B, up 8% YoY driven by JAKAFI and new product growth
  • Operating margin 22.4% vs 19.7% reflecting improved cost efficiencies
  • Best segment: Hematology $1.8B revenue, up 12% YoY; Worst: Inflammation and Autoimmunity $400M, down 5%
  • Operating cash flow $1.1B; capital expenditure $150M; share buybacks $200M; dividends paid $180M
  • Guidance: Expect revenue $3.7B-$3.9B in 2027; risk from JAKAFI patent loss in 2028 and competition

AI summary of the INCY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Total revenue $1,557.2M, up $191.2M YoY from $1,366.0M
  • Net loss $784.8M vs net income $424.2M YoY, driven by $1.23B Vega IPR&D expense
  • Best product OPZELURA, sales $254.9M vs $188.0M; worst ICLUSIG, $33.5M vs $37.6M
  • Cash, equivalents and marketable securities $3.9B; operating cash flow $201.7M vs $870.2M YoY
  • Outlook: cash resources adequate for foreseeable future; FDA povorcitinib decision anticipated first quarter 2027

Risk Factors

  • Newly added acquisition risk: July 2026 Vega Therapeutics acquisition creates integration, compliance and contingent-liability exposure
  • Most material patent risk: Generic JAKAFI manufacturers’ challenges remain pending against patents expiring December 2028
  • Regulatory risk: Inflation Reduction Act manufacturer discount obligations increase as Medicare Part D provisions phase out
  • Near-term commercial risk: OPZELURA generic challenges remain pending against patents expiring in 2031 and 2040
  • Financial risk: Global operations expose revenues and net income to unfavorable foreign-currency fluctuations

AI summary of the INCY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 8.01: Other Events

  • Phase 3 MAESTRA-3 ovarian cancer study canceled before planned fourth-quarter 2026 start
  • INCB123667 development continues without safety or efficacy concerns cited
Filed Oct 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results for quarter ended September 30, 2026
  • Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1.56B and net sales $1.32B, each up 14% YoY, confirming broad commercial momentum
  • Core growth accelerating beyond Jakafi: Opzelura sales $255M, up 36%, while Hematology and Oncology sales rose 38% to $235M
Filed Aug 31, 2026Full analysis →

Item 8.01: Other Events

  • CMS agreement expands state Medicaid access to Jakafi and Jakafi XR at internationally aligned prices
  • Incyte expects exemption from certain future CMS pricing mandates, including proposed GUARD and GLOBE models

AI summaries of INCY 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for INCY

Don't miss the next INCY filing

  • Alerts as it files. A push when INCY files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut INCY, by share count.
  • Ask anything. An AI agent that reads every INCY filing and answers with sources.

INCY alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
CAGNONI PABLO JSellNov 16, 2026$120.46
CAGNONI PABLO JMNov 16, 2026$61.18
CAGNONI PABLO JMNov 16, 2026$64.25
CAGNONI PABLO JSellNov 16, 2026$121.98
Stein Steven HSellNov 16, 2026$121.98
Stein Steven HMNov 16, 2026-
Stein Steven HMNov 16, 2026$68.25
CAGNONI PABLO JMNov 16, 2026$61.76

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$3.7B$4.2B$5.1B
Operating Income$620.5M$61.4M$1.5B
Net Income-$32.6M$1.3B
Op. Margin16.8%1.4%29.5%
Net Margin-0.8%25.0%
Balance Sheet
Total Assets-$5.4B$7.0B
Equity$5.2B$3.4B$5.2B
ROE-0.9%24.9%
Per Share
EPS$2.65$0.15$6.41
Cash Flow
Operating CF$496.5M$335.3M$1.4B
CapEx-$48.7M-

Source: XBRL data in Incyte (INCY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate INCY share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
INCY shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202639$9.59B
Q2 202642$8.85B
Q1 202636$7.30B
Q4 202536$7.68B
Q3 202537$6.69B
Q2 202534$5.32B
Q1 202534$3.57B
Q4 202430$3.43B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 288 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

INCY filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 17, 2026--
8-KNov 13, 2026Analysis-
4Nov 10, 2026--
4Nov 5, 2026--
8-KOct 29, 2026Analysis-
10-QOct 29, 2026Analysis
4Oct 19, 2026--
4Oct 5, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 24, 2026--
4Sep 17, 2026--
8-KAug 31, 2026Analysis-
4Aug 27, 2026--
4Aug 20, 2026--
4Aug 14, 2026--
4Aug 7, 2026--
4Aug 7, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
8-KJul 28, 2026Analysis-
10-QJul 28, 2026Analysis

Related Health Care companies

All Health Care →

INCY SEC filings: frequently asked questions

Are INCY insiders buying or selling?

In the last 90 days, Incyte (INCY) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $33.3 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold INCY stock?

As of September 30, 2026, the largest Incyte (INCY) holders among the 13F filers tracked by SignalX were BlackRock ($2.3 billion), Vanguard Capital Management LLC ($1.4 billion), State Street Corp ($1.2 billion), Vanguard Portfolio Management LLC ($943.3 million), AQR Capital Management ($677.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was INCY's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Incyte (INCY) reported revenue of $5.1 billion (up 21.2% from FY2024) and net income of $1.3 billion. Diluted EPS was $6.41. The figures come from the XBRL data in the 10-K.

What are the main risks in INCY's latest 10-K?

In the 10-K filed February 10, 2026, Incyte (INCY) flagged: Regulatory risk: ongoing contract dispute settlement expense of $242M recognized in fiscal 2025. Macroeconomic exposure: 93% of total revenues ($4.8B of $5.1B) from U.S. market concentration. (AI summary of the Risk Factors section.)

What did INCY report in its latest 8-K?

Incyte (INCY) filed an 8-K on November 13, 2026 reporting Item 8.01 (Other Events). Phase 3 MAESTRA-3 ovarian cancer study canceled before planned fourth-quarter 2026 start.

What are the latest INCY SEC filings?

Incyte (INCY) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on November 18, 2026.

What is INCY's SEC CIK number?

Incyte (INCY)'s SEC Central Index Key (CIK) is 879169. EDGAR lists every INCY filing under that number.

Ask anything about INCY

The research agent reads INCY's filings, financials, insider trades and 13F holders, then answers with sources.